Loading
A phase 2 trial of Ivonescimab, Cadonilimab, AK117 in small-cell lung cancer, run by Akeso, now recruiting.
A Study of Ivonescimab in First-Line ES-SCLC is a phase 2 interventional study registered as NCT07245446 by Akeso, with 180 participants planned, started 2025-10-29 and due to reach its primary completion in 2027-12. Interventions recorded: Ivonescimab, Cadonilimab, AK117, Etoposide, Carboplatin (AUC 5). Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Akeso, Ivonescimab, Bispecific antibodies, Carboplatin.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.